UPDATE: Roth Capital Cuts Pharmacyclics (PCYC) to Neutral; Sees FY15 Guidance, Market Expectations Priced into Shares
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Pharmacyclics (PCYC) Remains Rated Sector Perform at RBC, PT Raised to $145
February 19, 2015 9:04 AM ESTRBC Capital maintained a Sector Perform rating on Pharmacyclics (NASDAQ: PCYC) and raised its price target to $145.00 (from $130.00). Comments follow Q4 results. Analyst Michael J. Yee thinks bulls are in control of the stock.
"We predict stock likely to keep trending up... More
Nomura Securities Upgrades Pharmacyclics (PCYC) to Buy
February 19, 2015 6:59 AM ESTNomura Securities upgraded Pharmacyclics (NASDAQ: PCYC) from Neutral to Buy with a price target of $196.00 (from $195.00), saying the RESONATE-2 data is key to upside in 2015
Analyst M. Ian Somaiya commented, "Pharmacyclics management reaffirmed their 2015 US sales guidance of $1bn and more importantly confirmed results of... More
JPMorgan Downgrades Pharmacyclics (PCYC) to Neutral
February 19, 2015 6:55 AM ESTJPMorgan downgraded Pharmacyclics (NASDAQ: PCYC) from Overweight to Neutral with a price target of $173.00 (from $152.00).
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $170.21 yesterday.
... MorePharmacyclics (PCYC) Tops Q4 EPS by 20c
February 18, 2015 4:02 PM ESTPharmacyclics (NASDAQ: PCYC) reported Q4 EPS of $0.96, $0.20 better than the analyst estimate of $0.76. Revenue for the quarter came in at $290 million versus the consensus estimate of $267.5 million.
Worldwide Collaboration and License Agreement with Janssen
Under the Agreement, the repayment of... More
